185 related articles for article (PubMed ID: 34921042)
1. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
2. Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema.
Kikuchi Y; Odashima Y; Yoshikawa K; Oda T; Tanaka F; Oikawa H; Ishigaki Y; Asahi K
BMC Nephrol; 2022 Oct; 23(1):348. PubMed ID: 36309669
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.
Cheungpasitporn W; Chebib FT; Cornell LD; Brodin ML; Nasr SH; Schinstock CA; Stegall MD; Amer H
Transplantation; 2015 Nov; 99(11):2382-6. PubMed ID: 25905984
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
6. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review.
Hanna RM; Ahdoot RS; Kim MS; Jhaveri KD; Kalantar-Zadeh K; Kurtz IB
Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):47-56. PubMed ID: 34750330
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease.
O'Neill RA; Gallagher P; Douglas T; Little JA; Maxwell AP; Silvestri G; McKay G
BMC Nephrol; 2019 Dec; 20(1):478. PubMed ID: 31878889
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.
Hanna RM; Tran NT; Patel SS; Hou J; Jhaveri KD; Parikh R; Selamet U; Ghobry L; Wassef O; Barsoum M; Bijol V; Kalantar-Zadeh K; Pai A; Amin A; Kupperman B; Kurtz IB
Front Med (Lausanne); 2020; 7():579603. PubMed ID: 33117836
[TBL] [Abstract][Full Text] [Related]
10. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
11. Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting.
Brito P; Costa J; Gomes N; Costa S; Correia-Pinto J; Silva R
Acta Ophthalmol; 2020 Jun; 98(4):e421-e427. PubMed ID: 31742896
[TBL] [Abstract][Full Text] [Related]
12. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury.
Touzani F; Geers C; Pozdzik A
Case Rep Nephrol; 2019; 2019():2919080. PubMed ID: 31934470
[TBL] [Abstract][Full Text] [Related]
14. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy.
Davidović SP; Nikolić SV; Curić NJ; Latinović SL; Drašković DO; Cabarkapa VS; Stošić ZZ
Eur J Ophthalmol; 2012; 22(5):792-8. PubMed ID: 22344470
[TBL] [Abstract][Full Text] [Related]
15. Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF.
Brito P; Costa J; Gomes N; Costa S; Correia-Pinto J; Silva R
J Diabetes Complications; 2018 Jul; 32(7):643-649. PubMed ID: 29843962
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
17. Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: A case report and review of the literature.
Gan G; Michel M; Max A; Sujet-Perone N; Zevering Y; Vermion JC; Zaidi M; Savenkoff B; Perone JM
Br J Clin Pharmacol; 2023 Jan; 89(1):401-409. PubMed ID: 36208427
[TBL] [Abstract][Full Text] [Related]
18. [A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab].
Tomita M; Ochiai M; Shu S; Yamauchi Y; Shihara H; Ogata A; Fujisawa N; Yanai Y; Kamata T; Iehara N
Nihon Jinzo Gakkai Shi; 2014; 56(5):612-7. PubMed ID: 25130034
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT.
Kniggendorf VF; Novais EA; Kniggendorf SL; Xavier C; Cole ED; Regatieri CV
Arq Bras Oftalmol; 2016; 79(3):155-8. PubMed ID: 27463625
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.
Yahata M; Nakaya I; Sakuma T; Sato H; Aoki S; Soma J
BMC Res Notes; 2013 Nov; 6():450. PubMed ID: 24207130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
